Pre-Clinical Studies and Pharmacology of 13-Cis-Retinoic Acid in Neuroblastoma C. Patrick Reynolds, MD PhD Childrens Hospital Los Angeles University of.

Slides:

Advertisements

Similar presentations

& the certified athletic trainer

Advertisements

Building Global HIV/AIDS Clinical Pharmacology Research Capacity HIV and TB: Capacity Challenges to the use of Current Drugs and Developing New Drugs Kimberly.

Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.

FDA Pharmacogenetic Labels A Clinical Perspective David A Flockhart MD, PhD Indiana University School of Medicine Clinical Pharmacology Subcommittee of.

Flucoral® Pharmacological Composition Each capsule containing 150mg Fluconazole. Fluconazole is a broad spectrum Systemic Antifungal.

Sigma-aldrich.com/cellsignaling Transcription Activation by Nuclear Receptors.

Introduction to Pharmacology. Overview Pharmaceutics Pharmacokinetics Pharmacodynamics.

Retinoic Acid Receptor- Alpha and Its Role in Acute Promyelocytic Leukemia By Alex Sheng.

Ibrance® - Palbociclib

Retinoic Acid Receptor Alpha (RARα) Acute Promyelocytic Leukemia (APL)

Title, in bold style Subtitle, in regular Max 3 lines of text totally NB! The graphic outside the slide will not show in “Slide Show” or on print WntResearch.

Retinoic Acid Receptor Alpha and Acute Promyelocytic Leukemia Nidhi Thapar April 1, 2004.

Drug Formulation in Pediatrics: If it tastes bad it must be good for you Jeffrey Blumer, Ph.D., M.D. Professor of Pediatrics and Pharmacology Case Western.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

Basics of Pediatric Oncology Margret E. Merino, MD Pediatric Hematology/Oncology WRAMC.

DIFFERENTIAL EFFECTS OF LOW-DOSE AND HIGH-DOSE BETA-CAROTENE SUPPLEMENTION AND THE SIGNS OF PHOTOAGING AND TYPE I PROCOLLAGEN GENE EXPRESSION IN HUMAN.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Basis for Neulasta® (Pegfilgrastim) Approval

Food and Drug Administration Food and Drug Administration Center for Biologics Evaluation and Research Biological Response Modifiers Advisory Committee.

Richard D. Hockett, Jr. M.D. Sr. Clinical Research Physician Group Leader, Genomic Medicine FDA Clinical Pharmacology Advisory Committee Integrating Pharmacogenomics.

ArTiMist™ Clinical Trial Results By Mr Calvin Ross Sofitel Wentworth Hotel Sydney 14 April 2008 Eastland Medical Systems Ltd.

1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.

Arsenic Trioxide (ATO) in the Consolidation Treatment of Newly Diagnosed APL — First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian.

CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.

ONCOLOGY Drug Development Fadi Sami Farhat, MD ONCOLOGY Drug Development Fadi Sami Farhat, MD Hematology Oncology

Preclinical Models for Developing Therapy for Pediatric Solid Tumors Preclinical Models for Developing Therapy for Pediatric Solid Tumors uses and limitations.

APPLYING PRE-CLINICAL DATA TO CLINICAL STUDIES-I Edward A. Sausville, M.D., Ph.D. Developmental Therapeutics Program National Cancer Institute October.

Afsha Rais.  In chromatins, DNA is wrapped around proteins of which most are histones.  Histones assist in DNA packaging and have a regulatory role.

HOW CAN WE TAILOR DRUG DOSES IN EWING’S SARCOMA TO MAXIMISE BENEFIT AND MINIMISE SIDE EFFECTS?

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.

What Can We Learn From Pre-Clinical Drug Testing in Childhood Cancer?

What is Vitamin A ? Required for normal vision

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.

History of Pediatric Labeling

Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.

Retinoic Acid Receptor-α (RARα) & its role in Acute Promyelocytic Leukemia (APL) Danielle Matsushima.

Efficacy and Comparability of Thiazide-type Diuretics

Dinutuximab (ch14.18) for children with high-risk neuroblastoma

Cooperative Clinical Trials with 13-Cis-Retinoic Acid in Neuroblastoma Katherine K. Matthay, M.D University of California, San Francisco Children’s Oncology.

European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.

Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.

Drug Regulation, Development, Names, and Information Chapter 3 Copyright (c) 2004 Elsevier Inc. All rights reserved.

NCI Initiatives to Develop Non-Clinical Models for Pediatric Oncology Malcolm A. Smith, MD, PhD 17 March 2004.

1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

Retinoic Acid Receptor α Acute Promyelocytic Leukemia Michi Nair.

What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.

Division of Cancer Treatment and Diagnosis Presented By: Michael Difilippantonio, Ph.D. October 1, 2015.

Clinical Trials.

Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.

Drug Discovery &Development

Pembrolizumab Drugbank ID :DB09037 Half life : 28 days.

Senior Medical Director, Cardiovascular

Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells by Takayuki Ikezoe, Sakae Tanosaki, Utz Krug,

About Retinoids Dietary vitamin A—retinol—retinoic acid (RA).

Hadas Ben-Sasson, M. Sc. , Assaf Ben-Meir, M. D. , Asher Shushan, M. D

Mak Shu Ting (18) Yip Pui Yue (29)

Aging skin & Vitamin A (retinoids).

Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases Dhavalkumar D. Patel, MD, PhD, Christian Antoni,

Therapeutic Drug Monitoring chapter 1 part 1

Pediatric Formulation Development - A quality perspective

Genetic Factors in Congenital Diaphragmatic Hernia

Drug Therapy in Pediatric Patients

William H. Catherino, M.D., Ph.D., Minnie Malik, Ph.D.

Volume 15, Issue 4, Pages (April 2009)

Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105. Blockade of cell cycle at G2-M phase in Bel-7402 cells treated with IG-105.

Presentation transcript:

Pre-Clinical Studies and Pharmacology of 13-Cis-Retinoic Acid in Neuroblastoma C. Patrick Reynolds, MD PhD Childrens Hospital Los Angeles University of Southern California Children’s Oncology Group

Control 10  M Retinoic Acid High-Dose, Pulse Retinoic Acid Induces Neuroblastoma Differentiation

Regulation of Transcription by Retinoids Transcriptional Repression RARE ATRA RAR CPB/p300 9-cis-RA ACTR Activation of Transcription RXR AGGTCA 5bp AGGTCA RARE RXRRAR SMRT or N-coR mSin3a HDAC1 AGGTCA 5bp AGGTCA

Naturally Occurring Retinoids all trans-retinoic acid retinol (vitamin A) retinal 9-cis-retinoic acid 13-cis-retinoic acid

10  M Retinoic Acid Control Retinoic Acid Induces Prolonged Differentiation and Growth Arrest in SMS-LHN Day 28 (RA for 14 days, control passed x 4)

13-cis-Retinoic Acid Causes Sustained Growth Arrest of Neuroblastoma Neuroblastoma cell line given two pulses (2 weeks each) of 5  M 13-cis-retinoic acid MYCN protein expression by immunoblotting was down- regulated Phase I study achieved levels of  M peak and  M trough

Pharmacokinetics of 13-cis-Retinoic Acid

13-cis-RA Shows Stable AUC During Therapy

Formulation Sub-Optimal For Young Children Liquid in soft gelatin capsule (10, 20, 30, 40 mg) Can be pierced and chewed or children trained to swallow Often must be squeezed into food for young children causing increased dosing variability Out-of-capsule administration may be associated with decreased 13-cis-RA levels Veal et al, Br J Cancer 96:424, 2007 Extemporaneous liquid formulations have been associated with toxicity likely due to metabolism to ATRA

Drug Antagonism by 13-cis-RA in Neuroblastoma SMS-KCNR SMS-SAN

High-Risk Neuroblastoma Burden During Therapy 13-cis-RA ? LONG-TERM SURVIVAL

How can 13-cis-RA For Neuroblastoma Be Improved ? Isotretinoin labeling should include recommended dosing and approaches to use of the existing formulation in pediatric oncology Pharmacokinetic and possibly pharmacogenomic studies could allow for PK and/or PG-guided dosing Further study on administration route (in or out of capsule) effects on PK are needed A stable formulation suitable for young children and safe for handling by women of child-bearing potential would be optimal

Acknowledgements Clinical Trials Judy Villablanca Kate Matthay Bob Seeger Children’s Oncology Group Pharmacokinetics Vas Avramis Anis Khan The Patients and Parents who Participated in our Clinical Trials